,i #aaith ,,congress #b;d ,session ,h4 ,r4 #iigb ,,in ,,the ,,house ,,of ,,representatives ,july #bg1 #bjbf,mr4 ,sessions introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce1 and in addition to the ,committee on ,ways and ,means1 for a period to be subsequently determined by the ,speaker1 in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned ,a ,,bill ,to amend title ,,xviii of the ,social ,security ,act to adjust payment for skin substitute products under the ,medicare program4 #a4 ,short title ,this ,act may be cited as the ,american ,patients ,first ,act of #bjbf4 #b4 ,payment reform for skin substitute products 7a7 ,coverage of skin substitute products ,section #ahfa7s77#b7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciex7s77#b77 is amended-- 7#a7 in subparagraph 7,,jj71 by striking and at the end2 7#b7 in subparagraph 7,,kk71 by adding and at the end2 and 7#c7 by inserting after subparagraph 7,,kk7 the following new subparagraph3 7,,ll7 skin substitute products 7as defined in section #ahdg;,a7c77#f77;,j774 4 7b7 ,payment 7#a7 ,payment amount ,section #ahdg;,a of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#c;a7 is amended-- 7,a7 in subsection 7a77#a7-- 7i7 by striking the period at the end and inserting 2 and2 7ii7 by striking shall apply to and inserting shall apply-- 7,a7 to 2 and 7iii7 by adding at the end the following new subparagraph3 7,b7 to payment for skin substitute products 7as defined in subsection 7c77#f77;,j77 that are furnished during the period beginning on ,january #a1 #bjbg1 and ending on ,december #ca1 #bjcj4 2 and 7,b7 in subsection 7b7-- 7i7 in paragraph 7#a7-- 7,i7 in the text preceding subparagraph 7,a71 by inserting or a skin substitute product after drug or biological2 7,,ii7 in subparagraph 7,b71 by striking or at the end2 7,,iii7 in subparagraph 7,c71 by striking the period at the end and inserting 2 or2 and 7,,iv7 by adding at the end the following new subparagraph3 7,d7 in the case of a skin substitute product 7as defined in subsection 7c77#f77;,j77 furnished during the period beginning on ,january #a1 #bjbg1 and ending on ,december #ca1 #bjcj1 #deg per square centimeter4 2 and 7ii7 in paragraph 7#b7-- 7,i7 in subparagraph 7,a71 by inserting or a skin substitute product after drug or biological2 and 7,,ii7 in subparagraph 7,b71 by inserting 1 and1 with respect to a skin substitute product1 a square centimeter after pertaining to liquids4 7#b7 ,conforming amendments ,section #ahcc7;a77#a7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciel7a77#a77 is amended-- 7,a7 in subparagraph 7,s77i71 by striking subject to subparagraph 7,,ee7 and inserting subject to subparagraphs 7,,ee7 and 7,,ii72 7,b7 by striking and 7,,hh7 and inserting 7,,hh72 and 7,c7 by inserting 1 and 7,,ii7 with respect to skin substitute products under section #ahfa7s77#b77,,ll7 furnished during the period beginning on ,january #a1 #bjbg1 and ending on ,december #ca1 #bjcj1 the amount paid shall be #hj percent of the lesser of the actual charge or the payment amount established under section #ahdg;,a7b77#a77;,d7 before the semicolon at the end4 7c7 ,skin substitute product defined ,section #ahdg;,a7c77#f7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#c;a7c77#f77 is amended by adding at the end the following3 7,j7 ,skin substitute products 7i7 ,in general ,subject to clause 7ii71 the term skin substitute product-- 7,i7 means a cellular1 tissue1 biological or synthetic material that-- 7aa7 is applied to a wound and intended to remain within the wound bed2 and 7bb7 is marketed pursuant to section #eaj7k71 #eac7;f77#b71 or #eae of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 or section #cfa of the ,public ,health ,service ,act2 and 7,,ii7 includes any products reimbursed pursuant to skin substitutes codes under this title at any time prior to ,january #a1 #bjbg4 7ii7 ,exclusions ,the term skin substitute product does not include-- 7,i7 any product that is intended to temporarily protect or cover the wound bed and be removed without resorption such as a dressing2 or 7,,ii7 any product that does not meet the domestic sourcing and distribution requirements described in clause 7iii71 unless a waiver under clause 7iv7 is in effect with respect to such product4 7iii7 ,domestic sourcing and distribution requirements ,for purposes of clause 7ii71 the domestic sourcing and distribution requirements described in this clause are1 with respect to a product described in clause 7i71 the following3 7,i7 ,all human cellular or tissue material contained in such product was donated by citizens or nationals of the ,united ,states1 or aliens lawfully admitted for permanent residence in the ,united ,states1 and any such donation was made within the ,united ,states in accordance with applicable ,federal law4 7,,ii7 ,all harvesting and processing 7as applicable7 and all manufacturing of such product occurred exclusively within the ,united ,states1 and such harvesting1 processing1 and manufacturing was performed in compliance with all applicable standards of the ,food and ,drug ,administration and the ,american ,association of ,tissue ,banks4 7,,iii7 ,the product is distributed solely by the entity holding the applicable clearance1 approval1 or registration for such product under section #eaj7k71 #eac7;f77#b71 or #eae of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 or section #cfa of the ,public ,health ,service ,act1 and no intermediaries1 or agents were involved in the distribution of such product to the furnishing provider1 except that a third-party distributor that adheres to and is able to perform the contractual requirements associated with the scope of work and is qualified and able to adhere to the legal and regulatory requirements defined in the scope of work may be involved in such distribution4 7,,iv7 ,the entity described in subclause 7,,iii7 with respect to the product submits to the ,secretary1 in such form and manner as the ,secretary shall specify 7but not less frequently than annually71 an attestation that the product meets each of the requirements under subclauses 7,i7 through 7,,iii74 7iv7 ,waiver ,the ,secretary may waive the requirements under clause 7iii7 with respect to a specific product1 for a period not to exceed #ahj days1 if the ,secretary determines that a domestic supply shortage exists and that a waiver is necessary to protect patient access to care4 4 7d7 ,exclusion from reporting requirements ,section #ahdg;,a7f77#b77;,a7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#c;a7f77#b77;,a77 is amended by inserting 7except that1 beginning ,january #a1 #bjbg1 a drug or biological so described does not include a skin substitute product 7as defined in subsection 7c77#f77;,j777 after products that are payable under this part as a drug or biological4 7e7 ,consolidated billing and payment code ,not later than ,january #a1 #bjbg1 the ,secretary of ,health and ,human ,services shall establish a new billing and payment code for all skin substitute products 7as defined in subparagraph 7,j7 of section #ahdg;,a7c77#f7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#c;a7c77#f771 as added by subsection 7c774 #c4 ,enhancing program integrity for skin substitute products ,section #ahcd of the ,social ,security ,act 7#db ,u4,s4,c4 #aciem7 is amended by adding at the end the following new subsection3 7bb7 ,special payment rules for skin substitute products 7#a7 ,prepayment claim review and prior authorization 7,a7 ,initial prepayment claim review for certain providers 7i7 ,in general ,beginning ,january #a1 #bjbg1 the ,secretary shall conduct prepayment review of claims for skin substitute products submitted under this title by a specified provider of skin substitute products unless #a or more of the conditions described in clause 7ii7 is met with respect to such provider4 7ii7 ,limitation ,for purposes of clause 7i71 the conditions described in this subparagraph are1 with respect to a specified provider of skin substitute products1 the following3 7,i7 ,skin substitute products furnished by the provider are subject to prior authorization under subparagraph 7,b74 7,,ii7 ,the rate of approval for claims for skin substitute products furnished by such provider that are subject to prepayment review under this subparagraph exceeds #ij percent 7as determined over a period of time or number of claims specified by the ,secretary74 7,,iii7 ,the ,secretary determines that the billing practices of the provider are consistent with the applicable coverage criteria and requirements under this title4 7,b7 ,prior authorization for specified providers of skin substitute products 7i7 ,in general ,beginning not later than ,january #a1 #bjbh1 subject to clause 7ii71 the ,secretary shall1 for a period of #ahj days1 apply prior authorization for skin substitute products that are furnished by a specified provider of skin substitute products4 7ii7 ,removal from prior authorization ,in the event that the ,secretary determines1 with respect to a specified provider of skin substitute products1 that the rate of approval for requests for prior authorization under this subparagraph for skin substitute products furnished by such provider exceeds #ij percent 7as determined over a period of time or number of claims specified by the ,secretary71 the ,secretary shall cease to apply prior authorization under this paragraph for skin substitute products furnished by such provider4 7,c7 ,enrollment revocation or exclusion of noncompliant outlier providers 7i7 ,in general ,beginning ,january #a1 #bjbi1 if the rate of denial 7as determined after the exhaustion of all appeals and reviews7 for requests for prior authorization under subparagraph 7,b7 for skin substitute products furnished by an outlier provider of skin substitute products exceeds #ge percent over a period of #f or more consecutive months1 the ,secretary shall determine that an abuse of billing privileges exists with respect to such provider for purposes of section #dbd4ece7;a77#h77;ii7 of title #db1 ,code of ,federal ,regulations4 7ii7 ,referral for exclusion ,if the ,secretary determines under clause 7i7 that an abuse of billing privileges exists with respect to an outlier provider of skin substitute products1 the ,secretary shall direct the ,inspector ,general of the ,department of ,health and ,human ,services to determine whether such provider should be excluded from participation in any ,federal health care program under section #aabh7;b77#f74 7,d7 ,specified provider of skin substitute products defined 7i7 ,in general ,for purposes of this paragraph1 the term specified provider of skin substitute products means-- 7,i7 an outlier provider of skin substitute products1 as determined under clause 7ii72 7,,ii7 a provider with respect to which1 of all claims for payment under this title submitted in the preceding year1 #ae percent or more of such claims were for the provision of skin substitute products2 and 7,,iii7 as the ,secretary determines appropriate1 a provider of skin substitute products that-- 7aa7 is newly enrolled under section #ahff7;j72 7bb7 has undergone a change in ownership during the preceding year2 7cc7 is a high risk provider 7as determined by the ,secretary under section #dbd4eah of title #db1 ,code of ,federal ,regulations72 or 7dd7 has a pattern or practice of noncompliance with conditions of participation under this title or a high percentage of previously denied claims 7as determined by the ,secretary74 7ii7 ,identification of outlier providers of skin substitute products 7,i7 ,in general ,not later than ,december #a1 #bjbf1 and every #b years thereafter through ,december #a1 #bjcf1 the ,secretary shall determine the #c percent of the total number of providers of skin substitute products that are outlier providers of skin substitute products4 7,,ii7 ,outlier providers of skin substitute products ,the determination of an outlier provider of skin substitute products under this paragraph shall be based upon the providers 7as identified by national provider identification number7 that received the greatest total payment under this title for skin substitute products furnished in the year preceding the year in which the determination under subclause 7,i7 is made4 7,,iii7 ,referral to ,,oig ,the ,secretary shall-- 7aa7 make publicly available the list of outlier providers of skin substitute products identified under each determination under subclause 7,i72 and 7bb7 transmit such list to the ,inspector ,general of the ,department of ,health and ,human ,services for the assessment of potential fraud1 waste1 or abuse4 7,e7 ,funding ,for purposes of carrying out this paragraph1 the ,secretary shall provide for the transfer1 from the ,federal ,supplementary ,medical ,insurance ,trust ,fund under section #ahda1 to the ,centers for ,medicare ,medicaid ,services ,program ,management ,account1 of #b1ejj1jjj for each of fiscal years #bjbh through #bjca1 to remain available until expended4 7#b7 ,medicare coverage criteria for skin substitute products ,any skin substitute product furnished during #bjbg shall be subject to the same coverage criteria when determining whether the skin substitute product is covered under section #ahfb7;a77#a77;,a71 unless such product is determined by the ,secretary to be unsafe based on evidence of contamination1 serious infectious disease1 or serious adverse reactions caused by the product4 ,neither the ,secretary nor any ,medicare administrative contractor may determine1 including through a determination made pursuant to the prepayment review program or prior authorization program described in paragraphs 7#b7 and 7#c71 that a specific skin substitute product furnished in #bjbg is not covered under this title based solely on analysis of the clinical evidence relating to that skin substitute product4 7#c7 ,skin substitute product wastage 7,a7 ,in general ,with respect to skin substitute products furnished for the treatment of chronic or acute wounds1 payment may only be made under this title for the reasonable and necessary portion of the skin substitute product used in the treatment of the wound1 excluding wastage4 7,b7 ,reasonable and necessary defined ,for the purpose of subparagraph 7,a71 the term reasonable and necessary portion of the skin substitute product means the greater of-- 7i7 #cej square centimeters2 or 7ii7 #abj percent of the size of the treated wound4 7#d7 ,limitation on repeated applications ,payment may not be made under this title for more than #c distinct applications of a skin substitute product with respect to the same wound if1 in the clinical judgment of the provider furnishing such product1 there has been no improvement in the wound4 7#e7 ,certification requirement ,payment may only be made under this title for a skin substitute product if the provider furnishing such product is certified-- 7,a7 by the ,american ,board of ,wound ,management as a certified wound specialist or a certified wound care specialist physician2 7,b7 by the ,wound1 ,ostomy and ,continence ,nursing ,certification ,board as a certified wound care nurse practitioner2 7,c7 by the ,national ,alliance of ,wound ,care and ,ostomy as wound care certified2 or 7,d7 by the ,american ,foot ,care ,nurses ,association as a certified foot care specialist4 7#f7 ,limitation on provider discounts ,for the period beginning on ,january #a1 #bjbg1 and ending on ,december #ca1 #bjcj1 payment may not be made under this title for a skin substitute product if the provider furnishing such product obtained such product for less than #cdb4ge per square centimeter4 7#g7 ,skin substitute product defined ,in this subsection1 the term skin substitute product has the meaning given such term in section #ahdg;,a7c77#f77;,j74 4 #d4 ,report 7a7 ,in general ,not later than ,january #a1 #bjcj1 the ,secretary of ,health and ,human ,services shall submit to the appropriate committees of ,congress a report on the wound care industry1 including manufacturers of skin substitute products1 wound dressings1 and related wound management technologies4 ,such report shall include an analysis of-- 7#a7 the cost of producing skin substitute products in the ,united ,states2 and 7#b7 patient access to skin substitute products1 and the evidence supporting the effectiveness of such products4 7b7 ,definitions ,in this section3 7#a7 ,appropriate committees of ,congress ,the term appropriate committees of ,congress means-- 7,a7 the ,committee on ,energy and ,commerce and the ,committee on ,ways and ,means of the ,house of ,representatives2 and 7,b7 the ,committee on ,health1 ,education1 ,labor1 and ,pensions and the ,committee on ,finance of the ,senate4 7#b7 ,skin substitute product ,the term skin substitute product has the meaning given such term in subparagraph 7,j7 of section #ahdg;,a7c77#f7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#c;a7c77#f771 as added by section #b7;c74